Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort : The ABIDE project. / de Wilde, Arno; Ossenkoppele, Rik; Pelkmans, Wiesje; Bouwman, Femke; Groot, Colin; van Maurik, Ingrid; Zwan, Marissa; Yaqub, Maqsood; Barkhof, Frederik; Lammertsma, Adriaan A.; Biessels, Geert Jan; Scheltens, Philip; van Berckel, Bart N.; van der Flier, Wiesje M.

I: Alzheimer's and Dementia, 2019.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

de Wilde, A, Ossenkoppele, R, Pelkmans, W, Bouwman, F, Groot, C, van Maurik, I, Zwan, M, Yaqub, M, Barkhof, F, Lammertsma, AA, Biessels, GJ, Scheltens, P, van Berckel, BN & van der Flier, WM 2019, 'Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project', Alzheimer's and Dementia. https://doi.org/10.1016/j.jalz.2019.07.003

APA

CBE

de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, van Maurik I, Zwan M, Yaqub M, Barkhof F, Lammertsma AA, Biessels GJ, Scheltens P, van Berckel BN, van der Flier WM. 2019. Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. Alzheimer's and Dementia. https://doi.org/10.1016/j.jalz.2019.07.003

MLA

Vancouver

Author

de Wilde, Arno ; Ossenkoppele, Rik ; Pelkmans, Wiesje ; Bouwman, Femke ; Groot, Colin ; van Maurik, Ingrid ; Zwan, Marissa ; Yaqub, Maqsood ; Barkhof, Frederik ; Lammertsma, Adriaan A. ; Biessels, Geert Jan ; Scheltens, Philip ; van Berckel, Bart N. ; van der Flier, Wiesje M. / Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort : The ABIDE project. I: Alzheimer's and Dementia. 2019.

RIS

TY - JOUR

T1 - Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort

T2 - The ABIDE project

AU - de Wilde, Arno

AU - Ossenkoppele, Rik

AU - Pelkmans, Wiesje

AU - Bouwman, Femke

AU - Groot, Colin

AU - van Maurik, Ingrid

AU - Zwan, Marissa

AU - Yaqub, Maqsood

AU - Barkhof, Frederik

AU - Lammertsma, Adriaan A.

AU - Biessels, Geert Jan

AU - Scheltens, Philip

AU - van Berckel, Bart N.

AU - van der Flier, Wiesje M.

PY - 2019

Y1 - 2019

N2 - Introduction: The objective of this study was to assess the usefulness of the appropriate use criteria (AUC) for amyloid imaging in an unselected cohort. Methods: We calculated sensitivity and specificity of appropriate use (increased confidence and management change), as defined by Amyloid Imaging Taskforce in the AUC, and other clinical utility outcomes. Furthermore, we compared differences in post–positron emission tomography diagnosis and management change between “AUC-consistent” and “AUC-inconsistent” patients. Results: Almost half (250/507) of patients were AUC-consistent. In both AUC-consistent and AUC-inconsistent patients, post–positron emission tomography diagnosis (28%–21%) and management (32%–17%) change was substantial. The Amyloid Imaging Taskforce's definition of appropriate use occurred in 55/507 (13%) patients, detected by the AUC with a sensitivity of 93%, and a specificity of 56%. Diagnostic changes occurred independently of AUC status (sensitivity: 57%, specificity: 53%). Discussion: The current AUC are not sufficiently able to discriminate between patients who will benefit from amyloid positron emission tomography and those who will not.

AB - Introduction: The objective of this study was to assess the usefulness of the appropriate use criteria (AUC) for amyloid imaging in an unselected cohort. Methods: We calculated sensitivity and specificity of appropriate use (increased confidence and management change), as defined by Amyloid Imaging Taskforce in the AUC, and other clinical utility outcomes. Furthermore, we compared differences in post–positron emission tomography diagnosis and management change between “AUC-consistent” and “AUC-inconsistent” patients. Results: Almost half (250/507) of patients were AUC-consistent. In both AUC-consistent and AUC-inconsistent patients, post–positron emission tomography diagnosis (28%–21%) and management (32%–17%) change was substantial. The Amyloid Imaging Taskforce's definition of appropriate use occurred in 55/507 (13%) patients, detected by the AUC with a sensitivity of 93%, and a specificity of 56%. Diagnostic changes occurred independently of AUC status (sensitivity: 57%, specificity: 53%). Discussion: The current AUC are not sufficiently able to discriminate between patients who will benefit from amyloid positron emission tomography and those who will not.

KW - Alzheimer's disease

KW - Amyloid

KW - Appropriate use criteria

KW - Clinical practice

KW - Dementia

KW - Positron emission tomography

U2 - 10.1016/j.jalz.2019.07.003

DO - 10.1016/j.jalz.2019.07.003

M3 - Article

JO - Alzheimer's & Dementia

JF - Alzheimer's & Dementia

SN - 1552-5279

ER -